Merck & Company ( (MRK) ) has released its Q3 earnings. Here is a breakdown of the information Merck & Company presented to its ...

Merck reports Q3 sales of $16.7 billion, up 4% year-over-year, with Keytruda revenue rising 17%. EPS beats estimates; 2024 guidance updated on global demand shifts.

Merck's consistent dividend payments over 34 years, healthy balance sheet, and attractive valuation highlight its investment ...

But Merck's vaccine that prevents cancer from HPV, the most common sexually transmitted infection in the U.S., posted another quarter of lighter-than-expected sales. But Merck's vaccine that ...

Merck CEO Rob Davis dubs Keytruda market exclusivity loss as 'more of a hill than a cliff' Meanwhile, in the U.S., the company’s pneumococcal conjugate vaccine Capvaxive recently scored a key ...

(Reuters) - Merck & Co posted higher-than-expected third-quarter earnings on Thursday on strong sales of its blockbuster ...